Hutchmed Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Hutchison Medipharma Limited (to 2022)
3
Ending by 2030
May 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 30, 2027The maintenance fee for Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-yl)oxy)-N,2-Dimethylbenzofuran-3-Carboxamide (US 10,519,142) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-YL)OXY)-N,2-Dimethylbenzofuran-3-Carboxamide (US 11,958,838) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
- Aug 25 US 12,715,857 Tricyclic Compounds and Uses Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,829,574 | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases In force · USPTO record | In force | USPTO record | |
| US 8,212,033 | Use of substituted quinazoline compounds in treating angiogenesis-related diseases In force · USPTO record | In force | USPTO record | |
| US 8,658,658 | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use In force · USPTO record | In force | USPTO record | |
| US 10,519,142 | Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-yl)oxy)-N,2-Dimethylbenzofuran-3-Carboxamide In force · High confidence | In force | High confidence | |
| US 11,046,674 | Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-YL)OXY)-N,2-Dimethylbenzofuran-3-Carboxamide In force · High confidence | In force | High confidence | |
| US 11,958,838 | Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-YL)OXY)-N,2-Dimethylbenzofuran-3-Carboxamide In force · High confidence | In force | High confidence | |
| US 12,600,713 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide In force · High confidence | In force | High confidence | |
| US 12,030,951 | ANTI-OX40 Antibody and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,715,857 | Tricyclic Compounds and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending